- Price
- $227.99
- Day
- -2.44%
- Mkt Cap
- $14.63B
- 52W Range
- $101.00 – $244.49
- Volume
- 2.12M
- Beta
- 0.87
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Adjusted Operating Income: $579 million in Q2 2026.Adjusted Earnings Per Share: $4.02 in Q2 2026.Free Cash Flow: $256 million in Q2 2026.U.S. Dialysis Treatment
Read full article
DaVita NYSE: DVA reported second-quarter results that management said were broadly in line with expectations, supported by accelerating treatment-volume growth and lower mortality among patients. The kidney-care company reaffirmed its full-year 2026 guidance, while outlining plans to expand access to newer dialysis technology designed to improve clearance of so-called middle molecules.
Read full article
DaVita Inc. (DVA) Q2 2026 Earnings Call Transcript
Read full article
On August 4, 2026, DaVita Inc (DVA) released its 8-K filing, revealing financial and operational results for the quarter ended June 30, 2026. As one of the larg
Read full article
DENVER, Aug. 4, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June 30, 2026. "Thanks to the outstanding efforts of our teammates, we had another positive quarter for both patient outcomes and financial results," said Javier Rodriguez, CEO of DaVita Inc. "As we look to the rest of the year, we maintain our strategic focus on exciting new innovations in kidney dialysis to enhance the lives of our patients.
Read full article
DaVita said on Tuesday revenue per treatment was lower in the second quarter, blaming declining enrollments for dialysis treatments as patients dropped out of Obamacare plans following the end of pandemic-era subsidies.
Read full article
DaVita HealthCare (DVA) came out with quarterly earnings of $4.02 per share, beating the Zacks Consensus Estimate of $4.01 per share. This compares to earnings of $2.95 per share a year ago.
Read full article
DVA's Q2 results are likely to benefit from volume growth and RPT recovery, but payor mix pressure and spending on technology could limit margin gains.
Read full article
DVA's IKC momentum, higher 2026 guidance and technology investments support growth, while reimbursement and payer-mix risks cloud the outlook.
Read full article
In the latest trading session, DaVita HealthCare (DVA) closed at $239.46, marking a +1.33% move from the previous day.
Read full article
DENVER, July 21, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Tuesday, August 4, 2026, at 5:00 p.m. Eastern Time.
Read full article
DaVita HealthCare (DVA) reached $236.97 at the closing of the latest trading day, reflecting a +1.26% change compared to its last close.
Read full article